Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy

Summary Alterations in the balance of K‐Na‐2Cl cotransporter (NKCC1) and Na‐Cl cotransporter (KCC2) activity may cause depolarizing effect of γ‐aminobutyric Acid (GABA), and contribute to epileptogenesis in human temporal lobe epilepsy. NKCC1 facilitates accumulation of chloride inside neurons and f...

Full description

Saved in:
Bibliographic Details
Published in:Epilepsia (Copenhagen) 2013-01, Vol.54 (1), p.e9-e12
Main Authors: Eftekhari, Sanaz, Mehvari Habibabadi, Jafar, Najafi Ziarani, Massoumeh, Hashemi Fesharaki, Seyed Sohrab, Gharakhani, Marzieh, Mostafavi, Hossein, Joghataei, Mohammad Taghi, Beladimoghadam, Nahid, Rahimian, Elham, Hadjighassem, Mahmoud Reza
Format: Article
Language:English
Subjects:
Adult
Anticonvulsants - therapeutic use
Brain
Bumetanide
Bumetanide - therapeutic use
Chloride
Chloride transport
Depolarization
Drug therapy
Electroencephalography
Epilepsy
Epilepsy, Temporal Lobe - drug therapy
Epilepsy, Temporal Lobe - physiopathology
Firing pattern
GABA
gamma -Aminobutyric acid
Humans
Male
Neurons
NKCC1
Potassium-chloride cotransporter
Seizures
Seizures - drug therapy
Temporal lobe
Temporal lobe epilepsy
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Alterations in the balance of K‐Na‐2Cl cotransporter (NKCC1) and Na‐Cl cotransporter (KCC2) activity may cause depolarizing effect of γ‐aminobutyric Acid (GABA), and contribute to epileptogenesis in human temporal lobe epilepsy. NKCC1 facilitates accumulation of chloride inside neurons and favors depolarizing responses to GABA. In the current pilot study we provide the first documented look at efficacy of bumetanide, a specific NKCC1 antagonist, on reduction of seizure frequency in adult patients with temporal lobe epilepsy. According to our results, seizure frequency was reduced considerably in these patients. Furthermore, epileptiform discharges decreased in two of our patients. If the efficacy of bumetanide is proven in large scale studies, it can be used as a supplemental therapy in temporal lobe epilepsy.
ISSN:0013-9580
1528-1167
DOI:10.1111/j.1528-1167.2012.03654.x